Comparison of Methotrexate (NSC‐740) and Testosterone Propionate (NSC‐9166) in the Treatment of Breast Cancer

Nevinny, Hans B.; Hall, Thomas C.; Haines, Carleton R.; Krant, Melvin J.

doi:10.1002/j.1552-4604.1968.tb00258.x

Cited by 5 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some of the earliest published work in chemotherapy for brain tumors began in the 1950s and 1960s, focusing on use of systemic agents such as methotrexate, thioTEPA, nitrosoureas, and vinca alkaloids. [81–84] Kofman et al noted the use of prednisolone to reduce neurological symptoms in 1957. [85] Though the chemotherapy field has advanced, a regimen specific for the treatment of BCBM has yet to be approved and ratified by the Food and Drug Administration (FDA) or national and international cancer organizations.…”

Section: Subsets Of Breast Cancer Brain Metastasesmentioning

confidence: 99%

Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases

Shah

Mohammad

Saralkar

et al. 2018

Pharmacological Research

110

View full text Add to dashboard Cite

In women, breast cancer is the most common cancer diagnosis and second most common cause of cancer death. More than half of breast cancer patients will develop metastases to the bone, liver, lung, or brain. Breast cancer brain metastases (BCBM) confers a poor prognosis, as current therapeutic options of surgery, radiation, and chemotherapy rarely significantly extend life and are considered palliative. Within the realm of chemotherapy, the last decade has seen an explosion of novel chemotherapeutics involving targeting agents and unique dosage forms. We provide a historical overview of BCBM chemotherapy, review the mechanisms of new agents such as poly-ADP ribose polymerase inhibitors, cyclin-dependent kinase 4/6 inhibitors, phosphatidyl inositol 3-kinaseinhibitors, estrogen pathway antagonists for hormone-receptor positive BCBM; tyrosine kinase inhibitors, antibodies, and conjugates for HER2 BCBM; repurposed cytotoxic chemotherapy for triple negative BCBM; and the utilization of these new agents and formulations in ongoing clinical trials. The mechanisms of novel dosage formulations such as nanoparticles, liposomes, pegylation, the concepts of enhanced permeation and retention, and drugs utilizing these concepts involved in clinical trials are also discussed. These new treatments provide a promising outlook in the treatment of BCBM.

show abstract

Section: Subsets Of Breast Cancer Brain Metastasesmentioning

confidence: 99%

Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases

Shah

Mohammad

Saralkar

et al. 2018

Pharmacological Research

110

View full text Add to dashboard Cite

show abstract

“…Bei Monotherapien kSnnen Methotrexat (Nevinny et al, 1968), Melphalan (Sears et al, 1966) und Endoxan (Joslin et al, 1970;Rittmeyer et al, 1969) als bewghrt gelten. Bei letzterem verffigen wir im Wiener Arbeitskreis auch fiber eigene, gfinstige Ergebnisse nach Anwendung von 2 --3 Infusionen mit je 20--30 mg/kg in Abstgnden von 6 Tagen und mit der Fortsetzung der Therapie in 1--2 monatlichen Abst~nden mit 10 t£gigen Kurven von 400 mg/die (Boeekl et al, 1964;Boeckl et al, 1965;Boeckl u. Karrer, 1965;Boeckl et al, 1966).…”

Section: Cytostaticatherapie Beim Mammacarcinomunclassified

44. Cytostaticatherapie beim Mammacarcinom

Karrer¹

1970

Langenbecks Arch Chiv

View full text Add to dashboard Cite

“…IV IV IV IV IV IV weekly 0 (0/23) weekly 15.5 (7145) weekly 22.0 (7132) weekly 25.0 (4/16) weekly 33.0 (7/21) loading 36 (28) Hurley (29) 1v Zubrod Recently, Skipper and others (2)(3)(4) have demonstrated a relationshp between pharmacokinetic data and drug scheduling on cell kill. Mellet (5) has applied this knowledge to examine single agent drug scheduling for acute myelogenous leukemia in man.…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetic considerations in the design of optimal chemotherapeutic regimens for the treatment of breast carcinoma: A conceptual approach

Broder¹,

Carbone

1976

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

Pharmacological data are currently available for a number of antineoplastic agents which have shown clinical activity in advanced breast carcincoma. Preclinical data reveal a relationship between therapeutic response and certain pharmacokinetic parameters such as time of effective cytotoxic exposure (Teff) and the product of concentration with time (Cxt). We have attempted to apply human pharmacologic data to get estimates of these parameters for 6 active agents in breast cancer, to relate them to response rates, and to suggest a method for estimating the role of individual drugs in a multidrug combination. The response rates for 6 single agents were obtained from literature review and related to estimates of Teff and Cxt. The Cxt-response relations for single drugs were linear for cyclophosphamide, 5-fluorouracil, and thiotepa; exponential for vincristine; and relatively flat for methotrexate and cytoxine arabinoside. Most Teff values for the active single agents clustered about 15 hr/dose. From the graphs of response rate vs Cxt, the individual contribution of each agent in a combination study was estimated to arrive at a predicted response rate. The predicted response rates for the combination studies correlated with the actual response rates determined in the clinical study, for 6 of 6 nonrandomized studies and for 12 of 14 randomized studies analyzed. In 2 studies, deviations from the predicted response rate were attributed to differences in study design or analysis. There was no correlation between Teff and predicted response rate. Analyses of pharmacokinetic data may be useful to simulate combination chemotherapy studies to predict the effectiveness of clinical trials in breast cancer. Since the pharmacologic data were not obtained for any of the agents in the actual clinical trials done, we can only speculate on the usefulness of this method. We would encourage the prospective collection of this data in future clinical trails.

show abstract

Comparison of Methotrexate (NSC‐740) and Testosterone Propionate (NSC‐9166) in the Treatment of Breast Cancer

Cited by 5 publications

References 7 publications

Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases

Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases

44. Cytostaticatherapie beim Mammacarcinom

Pharmacokinetic considerations in the design of optimal chemotherapeutic regimens for the treatment of breast carcinoma: A conceptual approach

Contact Info

Product

Resources

About